SLC5A2 and chronic kidney disease: The evidence suggests that treatment of persons with T2D and CKD should consist of triple therapy with renin-angiotensin system blockade (ACE inhibitors or ARBs), SGLT2 inhibitors and finerenone, to slow the progression of CKD and reduce the risk of developing CV complications.